Literature DB >> 29038319

We need a "made in Canada" orphan drug framework.

Hugh J McMillan1, Craig Campbell2.   

Abstract

Mesh：

Year:  2017        PMID： 29038319      PMCID： PMC5647165          DOI： 10.1503/cmaj.170195

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  8 in total

1.  When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.

Authors:  Matthew Herder
Journal:  Account Res       Date:  2013       Impact factor: 2.622

2.  "Breakthrough" drugs and growth in expenditure on prescription drugs in Canada.

Authors:  Steven G Morgan; Kenneth L Bassett; James M Wright; Robert G Evans; Morris L Barer; Patricia A Caetano; Charlyn D Black
Journal:  BMJ       Date:  2005-09-02

3.  The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?

Authors:  Olivier Wellman-Labadie; Youwen Zhou
Journal:  Health Policy       Date:  2009-12-29       Impact factor: 2.980

4.  What is wrong with orphan drug policies?

Authors:  André Côté; Bernard Keating
Journal:  Value Health       Date:  2012-12       Impact factor: 5.725

Review 5.  Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.

Authors:  Ana M Valverde; Shelby D Reed; Kevin A Schulman
Journal:  Health Aff (Millwood)       Date:  2012-11       Impact factor: 6.301

6.  An Orphan Drug Framework (ODF) for Canada.

Authors:  David K Lee; Barbara Wong
Journal:  J Popul Ther Clin Pharmacol       Date:  2014-02-23

7.  Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.

Authors:  Richard S Finkel; Claudia A Chiriboga; Jiri Vajsar; John W Day; Jacqueline Montes; Darryl C De Vivo; Mason Yamashita; Frank Rigo; Gene Hung; Eugene Schneider; Daniel A Norris; Shuting Xia; C Frank Bennett; Kathie M Bishop
Journal:  Lancet       Date:  2016-12-07       Impact factor: 79.321

Review 8.  Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.

Authors:  Todd Gammie; Christine Y Lu; Zaheer Ud-Din Babar
Journal:  PLoS One       Date:  2015-10-09       Impact factor: 3.240
  8 in total
  2 in total

1.  Access to new drugs for rare disorders in Canada.

Authors:  Nigel S Rawson; John Adams
Journal:  CMAJ       Date:  2018-07-09       Impact factor: 8.262

2.  Clinical characteristics of patients from Quebec, Canada, with Morquio A syndrome: a longitudinal observational study.

Authors:  Lina Moisan; David Iannuzzi; Bruno Maranda; Philippe M Campeau; John J Mitchell
Journal:  Orphanet J Rare Dis       Date:  2020-09-29       Impact factor: 4.123
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.